Subject

Collection Time (h) e

Treatment

Parent / Metabolite(ng/mL)

Donepezil

M1/M2

M4

M6

 

A

482

 

 

Oral

365.1

1.0

5.5

3.6

648

118.6

0.9

0.7

0.8

 

B

482  

378.7

2.0

4.8

4.5

648

59.3

0.6

0.3

0.1

 

C

483  

248.8

0.9

3.9

5.7

648

104.9

0.6

0.8

trace

 

D

482  

456.3

0.7

7.1

6.6

636

155.1

0.6

1.1

0.4

 

E

482  

369.6

2.3

3.0

3.9

648

91.3

0.7

trace

trace

 

F

482  

369.6

1.9

5.1

7.1

648

77.6

0.8

0.8

0.7

 

G

H H

156

 

 

 

7 Day Patch

410.7

0.8

4.8

2.0

336

182.5

1.2

1.2

0.3

 

H

180

273.8

0.4

2.4

2.5

336

109.5

0.8

0.8

trace

 

I

156

319.4

0.9

2.5

2.2

336

110.9

0.7

0.6

0.3

 

J

120

365.1

0.8

3.2

3.0

312

136.9

1.2

0.8

trace

 

K

120

182.5

1.2

1.4

1.2

288

91.3

1.0

0.8

0.2

 

L

180

136.9

3.4

0.3

1.7

288

45.6

1.4

1.3

0.2

ecollection time represents a range of plasma concentrations for each subject
Table 3: Donepezil and Metabolite(s) Concentrations in Human Plasma after Repeated Oral Administration (10 mg tablet) or a Single Transdermal Patch (350 mg).